why choose us

First received: November 10, 2022

Clinical Trial: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Study Status: Completed

Recruit Status: Completed

Condition: Primary Immune Thrombocytopenia

Study Type: Interventional


Official Title: Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Trial

Brief Summary: QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with primary chronic ITP.

Read more